ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00370149
Recruitment Status : Terminated (Blinded interim analysis resulted in early termination of the study.)
First Posted : August 30, 2006
Results First Posted : February 24, 2016
Last Update Posted : February 24, 2016
Sponsor:
Information provided by (Responsible Party):
Indiana University ( Indiana University School of Medicine )

Brief Summary:
The primary purpose of the study is to determine if a therapeutic difference exists between central venous catheters impregnated with minocycline and rifampin and conventional catheters not impregnated with antibiotics when used in children at high risk for bloodstream infections (CABSI) after cardiac surgery.

Condition or disease Intervention/treatment Phase
Infection Prevention Device: Antibiotic-impregnated Catheters (M/R) Device: Non-impregnated Catheters (C/S) Phase 4

Detailed Description:
The standard central venous catheter (CVC) is now commonly used for infants, children, and adults. The antibiotic-coated CVC is a newer CVC gaining popularity for use in adults. The Food and Drug Administration (FDA) and the Center for Disease Control (CDC) support use of the antibiotic-coated CVC for adult patients. But the FDA and CDC have not yet endorsed use of the antibiotic-coated CVC for infants and children due to lack of research on this CVC in infants and children.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 326 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Controlled Trial of Catheter Related Infectious Event Rates Using Antibiotic-impregnated Catheters vs. Conventional Catheters in Pediatric Cardiovascular Surgery Patients
Study Start Date : September 2006
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics

Arm Intervention/treatment
Active Comparator: Antibiotic-impregnated Catheters (M/R)
Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter. The catheters are sized to accommodate children in different size ranges: Cook Inc. Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
Device: Antibiotic-impregnated Catheters (M/R)
Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.

Placebo Comparator: Non-impregnated Catheter (C/S)
Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
Device: Non-impregnated Catheters (C/S)
Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.




Primary Outcome Measures :
  1. Incidence of Catheter-related Bloodstream Infections (CRBSI) Per 1000 Catheter Days [ Time Frame: Participants were followed for the duration of the hospital stay, an average of 6 days. ]
    Rates of CRBSI defined as 1. micro-organism isolated from a blood culture; 2. Clinical manifestations of infection such as fever (≥38 C) and/or hypotension (defined according to age-related practice guidelines for systolic blood pressure); 3. No apparent source for the bloodstream infection except for the catheter.


Secondary Outcome Measures :
  1. Episodes of Clinical Sepsis and/or Infection With Identified Source Other Than Catheter [ Time Frame: Participants were followed for the duration of hospital stay, an average of 6 days. ]
    A secondary outcome measure was episodes of clinical sepsis and/or infection with identified source other than the CVC.

  2. Death [ Time Frame: Participants were followed for the duration of the hospital stay, an average of 6 days. ]
    Patient Death during hospitalization.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age < 18 years
  • Cardiovascular surgery patient with a case complexity warranting CVC placement longer than 3 days
  • Study devices of appropriate size for patient use without modification
  • Informed consent obtained prior to patient entering the operating room

Exclusion Criteria:

  • Age ≥ 18 years
  • Drug allergy to minocycline, other tetracyclines, or rifampin
  • Ventricular assist device (VAD) therapy
  • Extracorporeal membrane oxygenation (ECMO) therapy
  • Patients undergoing cardiac transplant
  • Any active infection or being treated for bacteremia at the time of randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00370149


Locations
United States, Indiana
Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University School of Medicine
Investigators
Principal Investigator: Elaine G. Cox, MD Indiana University School of Medicine

Additional Information:
Publications of Results:
Responsible Party: Indiana University School of Medicine
ClinicalTrials.gov Identifier: NCT00370149     History of Changes
Other Study ID Numbers: 0512-37
First Posted: August 30, 2006    Key Record Dates
Results First Posted: February 24, 2016
Last Update Posted: February 24, 2016
Last Verified: January 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Infection
Catheter-Related Infections
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents